New application of pyridines compound

Abstract

The invention discloses application of a pyridines compound in preparation of medicine for curing mycobacteria infectious diseases. The pyridines compound comprises a pyrazolopyridines compound and animidazopyridine compound; the structural general formula of the pyrazolopyridines compound is shown as formula (I), and the structural general formula of the imidazopyridine compound is shown as formula (II). The inventor firstly discovers that the pyrazolopyridines compound and the imidazopyridine compound can effectively cure mycobacteria infectious diseases, particularly diseases caused by theinfection of Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium leprae, and have the advantages of being convenient to use, quick to take effect, low in using dosage, low in toxic and side effects and the like.

Description

technical field [0001] The present invention relates to a new use of a pyridine compound, in particular to a use of a pyridine compound in preparing a medicine for treating mycobacterial infectious diseases. Background technique [0002] Mycobacterium ulcerans can cause severe skin ulcers, necrosis, and even blindness and death. It is often called Buruli Ulcer and has been found in Africa, Australia, Southeast Asia and South America , Japan and other regions found the disease. The treatment method for this disease is mainly to perform skin grafting after excision of the patient's tissue by surgical operation, but its cure rate is only between 16% and 28%, and it must be supplemented by drug treatment. The drug recommended by the World Health Organization for the treatment of this disease is a combination of rifampicin and streptomycin for about 8 weeks as adjuvant therapy. The therapy is based on previous experiments in mouse models. Other therapies (which have not entere...

AI Technical Summary

Problems solved by technology

In the standard drug therapy recommended by WHO, streptomycin needs to be injected daily for a long period of time, which is inconvenient for patients. The route of administration has a high risk of infection due to incomplete disinfection of equipment, and poor patient compliance

In addition, rifampicin and streptomycin have relatively large toxic and side effects, long-term administration, and poor patient compliance

There are few available drugs, all of which need to be combined with rifamycin drugs, so if the patient is resistant to this type of drug, the therapeutic effect of all therapies will be significantly reduced, and rifampicin and other drugs will significantly Decrease the efficacy of other disease treatment drugs, such as the AIDS drug Kaletra, and the use of the two together will make the antiviral effect of Kaletra ineffective

The long-term treatment effect of clarithromycin combined with rifampicin is poor, and it is still necessary to use streptomycin and rifampicin for consolidation therapy at a later stage

Bedaquiline, a new anti-tuberculosis drug, has relatively high toxicity and side effects. The FDA has added a black box to restrict its use. It is often recommended for the treatment of drug-resistant tuberculosis patients only when other drugs are ineffective. It has not yet been recommended for the treatment of Buruli necrosis.

Images